Description
Super filana (Avanafil + Dapoxetine) 100 mg + 60 mg
Super filana is a combination oral medicine containing avanafil and dapoxetine. Based on the verified ingredient information, avanafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction, while dapoxetine is a selective serotonin reuptake inhibitor (SSRI) used for premature ejaculation in adult men. This combination brings together two medicines with different mechanisms and safety considerations.
Active Ingredient and Medicine Class
Avanafil belongs to the PDE5 inhibitor class. It is a vasodilating medicine that supports penile blood flow during sexual stimulation.
Dapoxetine belongs to the SSRI class and is used on demand for premature ejaculation. It acts on serotonin pathways involved in ejaculatory control.
Established Medical Uses
Avanafil is established for the treatment of erectile dysfunction in adult men. Dapoxetine is established for the treatment of premature ejaculation in adult men aged 18 to 64 years.
These are the recognised uses of the individual ingredients. The fixed-dose combination itself may not have the same regulatory status in every country, so the precise approved indication should always be checked against the official product information for the local market.
How It Works
Avanafil helps relax smooth muscle in the penis by blocking PDE5, which increases the effect of nitric oxide and supports erection when sexual stimulation occurs.
Dapoxetine increases serotonin activity by blocking its reuptake. In general terms, this can help delay ejaculation and improve control over ejaculation.
Important Safety Information
Avanafil must not be used with nitrates or guanylate cyclase stimulators because of the risk of a marked drop in blood pressure. It also requires caution in people with cardiovascular disease, recent serious heart events, low blood pressure, severe liver disease, severe kidney impairment, or a history of vision or hearing problems linked to similar medicines.
Avanafil can interact with alpha-blockers, antihypertensive medicines, strong CYP3A4 inhibitors, and substantial alcohol intake.
Dapoxetine is not suitable for people with certain heart rhythm or heart problems, a history of fainting, moderate or severe liver impairment, or use of medicines that can interact with serotonin pathways. Important interaction concerns include MAO inhibitors, other serotonergic medicines, and some strong metabolic inhibitors. Because this product combines two active ingredients, the overall interaction burden may be greater than with either ingredient alone.
Possible Side Effects
Commonly reported adverse effects of avanafil include headache, flushing, nasal congestion, back pain, and nasopharyngitis. Serious but less common risks include priapism, sudden vision changes, and sudden hearing loss.
Common adverse effects of dapoxetine include nausea, dizziness, headache, diarrhoea, somnolence, and insomnia. Dapoxetine may also cause fainting in susceptible individuals.
Scientific Evidence
Clinical evidence supports avanafil as an effective PDE5 inhibitor for erectile dysfunction, with systematic reviews finding benefit in erectile function outcomes and an overall safety profile consistent with the class.
For dapoxetine, randomized trials and meta-analyses show improved intravaginal ejaculatory latency time and patient-reported control over ejaculation compared with placebo, although treatment-emergent adverse effects are common. Evidence for the specific fixed-dose combination is more limited than the evidence for each ingredient individually, so conclusions about the combination should be made cautiously.
Medical Information Notice
This page is an educational summary based on sources available at the time of review. It does not replace the official patient leaflet, national product information, or assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration — STENDRA (avanafil) tablets, prescribing information
- DailyMed / U.S. National Library of Medicine — Avanafil tablets, full prescribing information
- Medicines and Healthcare products Regulatory Agency / emc — Priligy (dapoxetine) patient leaflet
- Mark Sanford Avanafil: a review of its use in patients with erectile dysfunction. Drugs & Aging, 2013. View scientific article
- Sheridan M Hoy et al. Dapoxetine: in premature ejaculation. Drugs, 2010. View scientific article
